Moreover, in diabetic cases, the augmented availability of glucose causes an augmented availability of DAG, which activates PKC [ 34].
These results perfectly relate to the data on IL-1 β, since NALP3 is the principal molecule involved in the inflammasome processes, and inflammasome activation causes an augmented secretion of IL-1 β [ 22, 23].
During hypoglycemia, the attendant counterregulatory hormone response, mostly adrenergic, results in increases in heart rate and systolic blood pressure, which causes an augmented demand for coronary blood flow and oxygen consumption (7, 8) and may result in arrhythmia, ischemia, and death.
It is well established that both bone resorption and BFRs are increased during postmenopausal osteoporosis (Raisz, 2005; Feng and McDonald, 2011); however, the extent of increased bone resorption exceeds that of augmented bone formation, which causes an imbalance in favor of bone loss (Arlot et al., 1990; Ebeling et al., 1996; Tanizawa et al., 1999; Raisz, 2005; Eriksen, 2010).
This treatment also causes an appreciable decrease in HK activity, which may augment the effect of glucose transport on FDG incorporation.
Under these conditions there is an increased sympathetic adrenergic tone and reduced parasympathetic activity [ 3], a combination that causes augmented ventricular workload and oxygen demand, increasing the occurrence of ischemic events, and causes modification of the ionic currents across the cellular membrane, leading to direct electrical instability of myocytes.
Arterial stiffness causes an early return of the reflected pressure wave to the aorta, with subsequently augmented central systolic pressure.
First, the known proapoptotic effect of 5-FU that arises from the DNA damage it causes may be augmented in an additive manner by IFN- α, which may induce apoptosis by triggering the IFN- α/ β receptor, which can then activate the signal transducer and activator of transcription (STAT 1 protein; STAT1 in turn regulates the expression of the Bcl-2 family of apoptosis-related proteins.
Briefly speaking, the systemic effects are the reflection of a broad common pathology which ultimately causes an 'augmented' inflammation and impairment of immunocompetence during AKI [ 29, 30].
It is well known that intravenous administration of L-arginine causes vasodilatation and augmented blood flow in many vascular beds [ 19– 219.
The exact mechanism by which LLD causes or augments LBP, however, is not clear.
